These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38320181)

  • 1. Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma.
    Nordenmark LH; Hellqvist Å; Emson C; Diver S; Porsbjerg C; Griffiths JM; Newell JD; Peterson S; Pawlikowska B; Parnes JR; Megally A; Colice G; Brightling CE
    NEJM Evid; 2023 Oct; 2(10):EVIDoa2300135. PubMed ID: 38320181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
    Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
    Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
    Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
    Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
    N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tezepelumab in Adults with Uncontrolled Asthma.
    Corren J; Parnes JR; Wang L; Mo M; Roseti SL; Griffiths JM; van der Merwe R
    N Engl J Med; 2017 Sep; 377(10):936-946. PubMed ID: 28877011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
    Corren J; Menzies-Gow A; Chupp G; Israel E; Korn S; Cook B; Ambrose CS; Hellqvist Å; Roseti SL; Molfino NA; Llanos JP; Martin N; Bowen K; Griffiths JM; Parnes JR; Colice G
    Am J Respir Crit Care Med; 2023 Jul; 208(1):13-24. PubMed ID: 37015033
    [No Abstract]   [Full Text] [Related]  

  • 7. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
    Corren J; Pham TH; Garcia Gil E; Sałapa K; Ren P; Parnes JR; Colice G; Griffiths JM
    Allergy; 2022 Jun; 77(6):1786-1796. PubMed ID: 34913186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR.
    Laidlaw TM; Menzies-Gow A; Caveney S; Han JK; Martin N; Israel E; Lee JK; Llanos JP; Martin N; Megally A; Parikh B; Vong S; Welte T; Corren J
    J Asthma Allergy; 2023; 16():915-932. PubMed ID: 37692126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tezepelumab (Tezspire®) : new biological treatment of severe asthma].
    Schleich F; Sabbe M; Moermans C; Louis R
    Rev Med Liege; 2024 Jan; 79(1):60-64. PubMed ID: 38223972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
    Menzies-Gow A; Wechsler ME; Brightling CE; Korn S; Corren J; Israel E; Chupp G; Bednarczyk A; Ponnarambil S; Caveney S; Almqvist G; Gołąbek M; Simonsson L; Lawson K; Bowen K; Colice G;
    Lancet Respir Med; 2023 May; 11(5):425-438. PubMed ID: 36702146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
    Wechsler ME; Menzies-Gow A; Brightling CE; Kuna P; Korn S; Welte T; Griffiths JM; Sałapa K; Hellqvist Å; Almqvist G; Lal H; Kaur P; Skärby T; Colice G;
    Lancet Respir Med; 2022 Jul; 10(7):650-660. PubMed ID: 35364018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy.
    Corren J; Ambrose CS; Sałapa K; Roseti SL; Griffiths JM; Parnes JR; Colice G
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4334-4342.e6. PubMed ID: 34358701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Menzies-Gow A; Colice G; Griffiths JM; Almqvist G; Ponnarambil S; Kaur P; Ruberto G; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):266. PubMed ID: 33050934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asthma Control, Airway Mucus, and
    McIntosh MJ; Kooner HK; Eddy RL; Jeimy S; Licskai C; Mackenzie CA; Svenningsen S; Nair P; Yamashita C; Parraga G
    Chest; 2022 Sep; 162(3):520-533. PubMed ID: 35283104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation.
    Oguma A; Shimizu K; Kimura H; Tanabe N; Sato S; Yokota I; Takimoto-Sato M; Matsumoto-Sasaki M; Abe Y; Takei N; Goudarzi H; Suzuki M; Makita H; Hirai T; Nishimura M; Konno S;
    Allergol Int; 2023 Apr; 72(2):262-270. PubMed ID: 36402674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Menzies-Gow A; Ponnarambil S; Downie J; Bowen K; Hellqvist Å; Colice G
    Respir Res; 2020 Oct; 21(1):279. PubMed ID: 33087119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma.
    Sakai N; Koya T; Murai Y; Tsubokawa F; Tanaka K; Naramoto S; Aoki A; Shima K; Kimura Y; Watanabe S; Hasegawa T; Kikuchi T
    Int Arch Allergy Immunol; 2023; 184(8):783-791. PubMed ID: 37231966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    Dunican EM; Elicker BM; Gierada DS; Nagle SK; Schiebler ML; Newell JD; Raymond WW; Lachowicz-Scroggins ME; Di Maio S; Hoffman EA; Castro M; Fain SB; Jarjour NN; Israel E; Levy BD; Erzurum SC; Wenzel SE; Meyers DA; Bleecker ER; Phillips BR; Mauger DT; Gordon ED; Woodruff PG; Peters MC; Fahy JV;
    J Clin Invest; 2018 Mar; 128(3):997-1009. PubMed ID: 29400693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.
    Menzies-Gow A; Ambrose CS; Colice G; Hunter G; Cook B; Molfino NA; Llanos JP; Israel E
    Adv Ther; 2023 Nov; 40(11):4957-4971. PubMed ID: 37723356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Menzies-Gow A; Wechsler ME; Brightling CE
    Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.